Cancer Prevention II
More than 180 participants and experts from 31 countries met for the fifth time in 10 years in St. Gallen, Switzerland for a 3-day conference to discuss important current issues of clinical cancer prevention. The meeting was again organized and co-sponsored by St. Gallen Oncology Conferences (SONK). While SONK has been extremely successful in organizing large international c- gresses on “Primary Therapy of Early Breast Cancer” as well as “Supportive Care in Cancer” for more than 20 years, the idea of promoting interdisciplinary, clinically oriented meetings on cancer prevention is a more recent and not yet generally accepted and w- comed concept in modern oncology. Since today’s medical expenses are soaring and me- cal research budgets are stagnating or even being cut, neither politicians nor industry is willing to risk an additional unpredictable channel of expenses, such as that demanded by clinical cancer prevention efforts! In Switzerland—and we fear in many other parts of the globe—some 97%–98% or even a greater percentage of health budgets is spent for curative and palliative/rehabilitative m- icine. Since a meager 2%–3% of national health budgets is for preventive medicine, even less than that proportion is specifically allocated for cancer prevention. When the money for “curing and caring” for the diseased populace runs short, there is likely not much left for partly controversial disease prevention in the (still) healthy part of the population.
Was andere dazu sagen - Rezension schreiben
Es wurden keine Rezensionen gefunden.
Andere Ausgaben - Alle anzeigen
acid activity adenocarcinoma agents angiogenesis apoptosis aspirin assessed associated Barrett’s oesophagus bexarotene Biomarkers biopsy breast cancer breast cancer risk breast density Cancer Epidemiol Biomarkers cancer incidence Cancer Prevention Trial Cancer Res carcinogenesis carcinoma Case-control studies celecoxib chemoprevention Clin clinical trials cohort studies colorectal cancer detection dietary disease dose drugs effect Epidemiol Biomarkers Prev epidemiological ER-negative breast cancer estrogen fenretinide follow-up gene growth factor Hans-Jörg Senn HBV vaccination hepatitis hormone IGF-I IGFBP-3 inhibit inhibitors insulin intervention invasive breast cancer Kaaks kinase levels lifestyle mammary mammographic density markers metabolism metformin mice mortality Natl Cancer Inst NSAIDs Nutrition oesophagus Oncol Oncology ovarian cancer pathways patients placebo population postmenopausal postmenopausal women potential prevention programs proliferation prostate cancer raloxifene randomized receptor reduced retinoid risk of breast SELECT selenium serum tamoxifen target therapy tion tissue toxicity treatment tumor Urol vitamin vitamin E